Biotech Startup Yumanity Therapeutics Launched To Develop New Therapies for Neurodegenerative Diseases Caused by Protein Misfolding

Biotech Startup Yumanity Therapeutics Launched To Develop New Therapies for Neurodegenerative Diseases Caused by Protein Misfolding
colesTBiotech industry veteran Tony Coles, M.D. has launched a new startup -- Cambridge, Massachusetts-based Yumanity Therapeutics. Founded in December 2014, the new company's central focus is on drug discovery for diseases caused by a DNA anomaly called "protein misfolding." Yumanity Therapeutics' founders include by Dr. Coles, who is chairman and chief executive officer, and scientific founder Susan Lindquist, Ph.D., an award-winning pioneer and expert on the foundational science of protein folding, Yumanity's corporate mission is to identify and then develop disease-modifying therapies LindquistHHMIdesigned to address several illnesses, the medical needs of which are currently being critically unmet. The company's initial focus is trained on neurodegenerative diseases, including Alzheimer's and Parkinson's diseases and amyotrophic lateral sclerosis (ALS). Yumanity's proprietary platforms have already identified a potential new target for Parkinson's treatment, and the scientific team will commence work immediately on taking its new chemical lead series for this illness forward, and on identifying additional compounds for address of Alzheimer's and ALS. Yumanity's founders note that br
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *